<DOC>
	<DOCNO>NCT01203618</DOCNO>
	<brief_summary>The purpose study evaluate whether therapy farletuzumab effective safe treatment resectable , non-functioning pituitary adenoma .</brief_summary>
	<brief_title>Exploratory Study Farletuzumab Treat Resectable , Non-functioning Pituitary Adenomas</brief_title>
	<detailed_description>Non-functioning pituitary adenoma frequent type pituitary tumor , define lack hormonal overproduction tumor . Non-functioning macroadenomas &gt; 1 cm size cause progressive visual loss , headache , symptom pituitary dysfunction ( hypopituitarism and/or hyperprolactinemia ) . Initial treatment type tumor trans sphenoidal surgical resection . In case outcome incomplete surgical resection tumor , repeat surgery external beam radiation therapy may perform . Previous clinical work suggest may role folate receptor treatment non-secretory , pituitary adenoma . MORAb-003 monoclonal antibody potential effective agent resectable , non-functioning pituitary adenoma . MORAb-003 show well tolerate . This study allow opportunity determine therapy farletuzumab effective safe .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<criteria>Males female &gt; 18 year old Diagnosis nonfunctional pituitary adenoma Able willing undergo surgical resection pituitary tumor Significant medical condition must wellcontrolled stable least 30 day prior sign inform consent form Presence clinically significant pituitary apoplexy Presence hormonesecreting adenomas Presence compressive optic neuropathy due pituitary tumor No prior surgical , medical , radiation therapy last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Resectable , non-functioning pituitary adenoma</keyword>
	<keyword>Pituitary tumor</keyword>
	<keyword>Pituitary adenoma</keyword>
	<keyword>Pituitary macroadenoma</keyword>
</DOC>